{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,8]],"date-time":"2024-09-08T09:41:41Z","timestamp":1725788501039},"reference-count":131,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2013,5,1]],"date-time":"2013-05-01T00:00:00Z","timestamp":1367366400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Problems in Cardiology"],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1016\/j.cpcardiol.2012.12.004","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T06:19:03Z","timestamp":1366179543000},"page":"165-206","source":"Crossref","is-referenced-by-count":10,"title":["Management of Coronary Atherosclerosis and Acute Coronary Syndromes in Patients With Chronic Kidney Disease"],"prefix":"10.1016","volume":"38","author":[{"given":"Karthiek R.","family":"Narala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohail","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"LaLonde","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter A.","family":"McCullough","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.cpcardiol.2012.12.004_bib2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1161\/CIRCULATIONAHA.107.188208","volume":"117","author":"King","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib3","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.jacc.2007.02.013","volume":"50","author":"Anderson","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib4","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1159\/000327230","article-title":"Treatment disparities in acute coronary syndromes, heart failure, and kidney disease","volume":"171","author":"McCullough","year":"2011","journal-title":"Contrib Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib5","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1046\/j.1525-139X.2003.16031.x","article-title":"Uremia-related metabolic cardiac risk factors in chronic kidney disease","volume":"16","author":"Madore","year":"2003","journal-title":"Semin Dial"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib6","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1001\/jama.296.11.1377","article-title":"Underrepresentation of renal disease in randomized controlled trials of cardiovascular disease","volume":"296","author":"Coca","year":"2006","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib7","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1093\/ndt\/gfm689","article-title":"Mortality, kidney disease and cardiac procedures following acute coronary syndrome","volume":"23","author":"Inrig","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib8","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1161\/CIRCULATIONAHA.106.177321","volume":"114","author":"Brosius","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib9","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med"},{"issue":"4 suppl 2","key":"10.1016\/j.cpcardiol.2012.12.004_bib10","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1053\/j.ajkd.2007.12.017","article-title":"CKD and cardiovascular disease in screened high-risk volunteer and general populations: the kidney early evaluation program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004","volume":"51","author":"McCullough","year":"2008","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib11","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"issue":"3 Suppl 2","key":"10.1016\/j.cpcardiol.2012.12.004_bib13","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1053\/j.ajkd.2010.11.007","article-title":"Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP)","volume":"57","author":"Stevens","year":"2011","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib14","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/j.jacc.2011.07.010","article-title":"Chronic kidney disease and risk for presenting with acute myocardial infarction versus stable exertional angina in adults with coronary heart disease","volume":"58","author":"Go","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib15","doi-asserted-by":"crossref","first-page":"2464","DOI":"10.1001\/archinte.162.21.2464","article-title":"Emergency evaluation of chest pain in patients with advanced kidney disease","volume":"162","author":"McCullough","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib16","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1016\/j.jacc.2006.05.047","article-title":"Cardiovascular risk among adults with chronic kidney disease, with or without prior myocardial infarction","volume":"48","author":"Wattanakit","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib17","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1016\/j.amjcard.2008.07.060","article-title":"The case for chronic kidney disease, diabetes mellitus, and myocardial infarction being equivalent risk factors for cardiovascular mortality in patients older than 65 years","volume":"12","author":"Rashidi","year":"2008","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib18","doi-asserted-by":"crossref","first-page":"332","DOI":"10.4065\/mcp.2009.0513","article-title":"In-hospital major clinical outcomes in patients with chronic renal insufficiency presenting with acute coronary syndrome: data from a registry of 8176 patients","volume":"85","author":"El-Menyar","year":"2010","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib19","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.291.22.2727","article-title":"A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry","volume":"291","author":"Eagle","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib20","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1001\/archinte.163.19.2345","article-title":"Predictors of hospital mortality in the global registry of acute coronary events","volume":"163","author":"Granger","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib21","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1097\/01.crd.0000148162.88296.9f","article-title":"Increased prevalence of coronary artery disease, silent myocardial ischemia, complex ventricular arrhythmias, atrial fibrillation, left ventricular hypertrophy, mitral annular calcium, and aortic valve calcium in patients with chronic renal insufficiency","volume":"14","author":"Das","year":"2006","journal-title":"Cardiol Rev"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0735-1097(00)00774-9","article-title":"Risks associated with renal dysfunction in patients in the coronary care unit","volume":"36","author":"McCullough","year":"2000","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib23","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.amjmed.2005.08.057","article-title":"Chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes","volume":"119","author":"Han","year":"2006","journal-title":"Am J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib24","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/j.ahj.2003.12.010","article-title":"Renal insufficiency and mortality from acute coronary syndromes","volume":"147","author":"Masoudi","year":"2004","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0828-282X(06)70249-5","article-title":"Treatment and one-year outcome of patients with renal dysfunction across the broad spectrum of acute coronary syndromes","volume":"22","author":"Yan","year":"2006","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib26","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/S0002-9149(03)00147-4","article-title":"Renal function and risk stratification in acute coronary syndromes","volume":"91","author":"Wison","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2006.02.056","article-title":"Biomarkers in acute cardiac disease: the present and the future","volume":"48","author":"Jaffe","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib28","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.1161\/01.CIR.95.8.2053","article-title":"Prognostic influence of elevated values of cardiac troponin I in patients with unstable angina","volume":"95","author":"Galvani","year":"1997","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib29","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0735-1097(02)02608-6","article-title":"Cardiac troponins in renal insufficiency: review and clinical implications","volume":"40","author":"Freda","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib30","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1053\/ajkd.2002.33914","article-title":"Troponin is related to left ventricular mass and predicts all-cause and cardiovascular mortality in hemodialysis patients","volume":"40","author":"Mallamaci","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib31","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1056\/NEJMoa013456","article-title":"Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction","volume":"346","author":"Aviles","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib32","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1053\/j.ajkd.2005.06.008","article-title":"Delay in time to receipt of thrombolytic medication among Medicare patients with kidney disease","volume":"46","author":"Newsome","year":"2005","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib33","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","article-title":"Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients","volume":"324","year":"2002","journal-title":"BMJ"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib34","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/ajkd.2002.35680","article-title":"Left ventricular geometry and adverse cardiovascular events in chronic hemodialysis patients on prolonged therapy with ACE inhibitors","volume":"40","author":"Paoletti","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib35","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1159\/000049060","article-title":"Angiotensin II type 1 receptor antagonist, losartan, causes regression of left ventricular hypertrophy in end-stage renal disease","volume":"90","author":"Shibasaki","year":"2002","journal-title":"Nephron"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib36","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1161\/CIR.0b013e31820f2f3e","volume":"123","author":"Wright","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib37","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/j.1525-139X.2009.00697.x","article-title":"Antihypertensive agents in hemodialysis patients: a current perspective","volume":"23","author":"Inrig","year":"2010","journal-title":"Semin Dial"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib38","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (study of heart and renal protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib40","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib41","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2215\/CJN.04371206","article-title":"Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the treating to new targets (TNT) study","volume":"2","author":"Shepherd","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib42","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib43","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1111\/j.1600-6143.2004.00445.x","article-title":"Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients: post-hoc subgroup analyses of the ALERT study","volume":"4","author":"Jardine","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib44","doi-asserted-by":"crossref","first-page":"98","DOI":"10.7326\/0003-4819-138-2-200301210-00010","article-title":"Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency","volume":"138","author":"Tonelli","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib45","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1160\/TH11-06-0422","article-title":"Venous and arterial thrombosis in dialysis patients","volume":"106","author":"Ocak","year":"2011","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib46","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0272-6386(03)00860-6","article-title":"Hypercoagulability, a serious problem in patients with ESRD on maintenance hemodialysis, and its correction after kidney transplantation","volume":"42","author":"Nampoory","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib47","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0002-9149(03)00970-6","article-title":"Bivalirudin provides increasing benefit with decreasing renal function: a meta-analysis of randomized trials","volume":"92","author":"Chew","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib48","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1016\/j.jacc.2011.02.009","volume":"57","author":"Wright","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib49","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1445-5994.2010.02361.x","article-title":"An invasive management strategy is associated with improved outcomes in high-risk acute coronary syndromes in patients with chronic kidney disease","volume":"41","author":"Medi","year":"2011","journal-title":"Int Med J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib50","first-page":"92509","article-title":"Analysis of long-term survival after revascularization in patients with chronic kidney disease presenting with acute coronary syndromes","author":"Keeley","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib51","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2005.11.028","article-title":"Should primary percutaneous coronary intervention be the preferred method of reperfusion therapy for patients with renal failure and ST-elevation acute myocardial infarction?","volume":"97","author":"Dragu","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib52","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1161\/CIRCULATIONAHA.108.838169","volume":"120","author":"Szummer","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib53","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1093\/eurheartj\/ehp014","article-title":"Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction","volume":"30","author":"Wong","year":"2009","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib54","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.2215\/CJN.05551008","article-title":"Early angiography in patients with chronic kidney disease: a collaborative systematic review","volume":"4","author":"Charytan","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib55","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1016\/j.jacc.2009.10.015","volume":"54","author":"Kushner","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib56","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1161\/CIRCULATIONAHA.106.671644","article-title":"Cardiac angiography in renally impaired patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease","volume":"115","author":"Solomon","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib57","doi-asserted-by":"crossref","first-page":"e637S","DOI":"10.1378\/chest.11-2306","article-title":"Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Vandvik","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib58","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1016\/S0002-9149(02)02308-1","article-title":"Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency","volume":"89","author":"Jeremias","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib59","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0002-9149(01)02267-6","article-title":"Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with abciximab","volume":"89","author":"Frilling","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib60","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0002-8703(03)00231-X","article-title":"Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions","volume":"146","author":"Best","year":"2003","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib61","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/S0735-1097(02)02956-X","article-title":"Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb\/IIIa inhibitors","volume":"41","author":"Freeman","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib62","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1056\/NEJM199905273402103","article-title":"Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina. (CAPTURE) Study Investigators","volume":"340","author":"Hamm","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib63","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/S0140-6736(99)10285-X","article-title":"Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban","volume":"354","author":"Heeschen","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib64","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1001\/jama.2009.1800","article-title":"Contraindicated medication use in dialysis patients undergoing percutaneous coronary intervention","volume":"302","author":"Tsai","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib65","doi-asserted-by":"crossref","first-page":"445","DOI":"10.7326\/0003-4819-156-6-201203200-00007","article-title":"Effects of antiplatelet therapy on mortality and cardiovascular and bleeding outcomes in persons with chronic kidney disease: a systematic review and meta-analysis","volume":"156","author":"Palmer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib66","doi-asserted-by":"crossref","first-page":"670S","DOI":"10.1378\/chest.08-0691","article-title":"Antithrombotic therapy for non-ST-segment elevation acute coronary syndromes: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)","volume":"133","author":"Harrington","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib67","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jacc.2007.07.042","article-title":"Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial","volume":"50","author":"Mehta","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib68","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1378\/chest.125.3.856","article-title":"Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs enoxaparin","volume":"125","author":"Thorevska","year":"2004","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib69","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0735-1097(96)00447-0","article-title":"Troponin T identifies patients with unstable coronary artery disease who benefit from long-term antithrombotic protection","volume":"29","author":"Lindahl","year":"1997","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib70","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1056\/NEJM199708143370702","article-title":"A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-Wave Coronary Events Study Group","volume":"337","author":"Cohen","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib71","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1002\/ajh.1077","article-title":"Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin","volume":"67","author":"Busby","year":"2001","journal-title":"Am J Hematol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib72","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1592\/phco.20.9.771.35210","article-title":"Enoxaparin and bleeding complications: a review in patients with and without renal insufficiency","volume":"20","author":"Gerlach","year":"2000","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib73","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJMoa055443","article-title":"Comparison of fondaparinux and enoxaparin in acute coronary syndromes","volume":"354","author":"Yusuf","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib74","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1056\/NEJMoa0708191","article-title":"Bivalirudin during primary PCI in acute myocardial infarction","volume":"358","author":"Stone","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib75","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1016\/S0140-6736(11)60764-2","article-title":"Heparin plus a glycoprotein IIb\/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial","volume":"377","author":"Stone","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib76","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1105819","article-title":"Apixaban with antiplatelet therapy after acute coronary syndrome","volume":"365","author":"Alexander","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib77","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/S0140-6736(03)14287-0","article-title":"Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial","volume":"362","author":"Wallentin","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib78","doi-asserted-by":"crossref","first-page":"2781","DOI":"10.1093\/eurheartj\/ehr113","article-title":"Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial","volume":"32","author":"Oldgren","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib79","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib80","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1378\/chest.122.2.669","article-title":"The independent association of renal dysfunction and arrhythmias in critically ill patients","volume":"122","author":"Soman","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib81","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1056\/NEJMp1103050","article-title":"Anticoagulant options\u2014why the FDA approved a higher but not a lower dose of dabigatran","volume":"364","author":"Beasley","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib82","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa1112277","article-title":"Rivaroxaban in patients with a recent acute coronary syndrome","volume":"366","author":"Mega","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib83","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral Rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib84","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1001\/jama.286.10.1187","article-title":"Aspirin use and all-cause mortality among patients being evaluated for known or suspected coronary artery disease: a propensity analysis","volume":"286","author":"Gum","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib85","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.107.187930","volume":"116","author":"Fraker","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib86","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/S0735-1097(03)00241-9","article-title":"Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial","volume":"41","author":"Cice","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib87","doi-asserted-by":"crossref","first-page":"550","DOI":"10.7326\/0003-4819-134-7-200104030-00008","article-title":"Beta-blockers in congestive heart failure","volume":"134","author":"Brophy","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib88","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1046\/j.1523-1755.1999.00359.x","article-title":"Supervised atenolol therapy in the management of hemodialysis hypertension","volume":"55","author":"Agarwal","year":"1999","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib89","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1177\/089686089701700604","article-title":"Beta-blockers may cause ultrafiltration failure in peritoneal dialysis patients","volume":"17","author":"Stegmayr","year":"1997","journal-title":"Perit Dial Int"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib90","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib91","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib92","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib93","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/bmj.1.5540.617","article-title":"Nitrites and nitrates in the treatment of ischaemic heart disease","volume":"1","year":"1967","journal-title":"Br Med J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib94","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1159\/000063515","article-title":"Comparison of dialysis and clinical characteristics of patients with frequent and occasional hemodialysis-associated hypotension","volume":"25","author":"Tisl\u00e9r","year":"2002","journal-title":"Kidney Blood Press Res"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib95","doi-asserted-by":"crossref","first-page":"9","DOI":"10.7326\/0003-4819-140-1-200401060-00006","article-title":"The prevalence of nontraditional risk factors for coronary heart disease in patients with chronic kidney disease","volume":"140","author":"Muntner","year":"2004","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib96","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1016\/j.jacc.2007.11.072","article-title":"Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (treating to new targets) study","volume":"51","author":"Shepherd","year":"2008","journal-title":"J Am Coll Cardiol"},{"issue":"12 Suppl 3","key":"10.1016\/j.cpcardiol.2012.12.004_bib97","doi-asserted-by":"crossref","first-page":"S231","DOI":"10.1681\/ASN.2006080938","article-title":"Effects of atorvastatin on inflammatory and fibrinolytic parameters in patients with chronic kidney disease","volume":"17","author":"Goicoechea","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib98","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/jcp.2003.012989","article-title":"The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease","volume":"57","author":"Athyros","year":"2004","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib99","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib100","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa043545","article-title":"Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis","volume":"353","author":"Wanner","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib101","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","article-title":"Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial","volume":"291","author":"Chaitman","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib102","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","article-title":"Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina","volume":"43","author":"Chaitman","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib103","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1001\/jama.297.16.1775","article-title":"Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial","volume":"297","author":"Morrow","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib104","doi-asserted-by":"crossref","first-page":"469","DOI":"10.2165\/00003088-200645050-00003","article-title":"Clinical pharmacokinetics of ranolazine","volume":"45","author":"Jerling","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib105","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.clpt.2005.05.004","article-title":"Effect of renal impairment on multiple-dose pharmacokinetics of extended-release ranolazine","volume":"78","author":"Jerling","year":"2005","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib106","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1161\/01.HYP.0000107251.49515.c2","article-title":"Seventh report of the joint National Committee on Prevention, detection, evaluation, and treatment of high blood pressure","volume":"42","author":"Chobanian","year":"2003","journal-title":"Hypertension"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib107","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11886-011-0215-0","article-title":"What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?","volume":"13","author":"Khouri","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib108","doi-asserted-by":"crossref","first-page":"541","DOI":"10.7326\/0003-4819-154-8-201104190-00335","article-title":"Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier","volume":"154","author":"Upadhyay","year":"2011","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib109","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1007\/s11886-011-0215-0","article-title":"What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease?","volume":"13","author":"Khouri","year":"2011","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib110","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1001\/archinternmed.2011.619","article-title":"Blood pressure components and end-stage renal disease in persons with chronic kidney disease: the kidney early Evaluation Program (KEEP)","volume":"172","author":"Peralta","year":"2012","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib111","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0140-6736(09)60212-9","article-title":"Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials","volume":"373","author":"Heerspink","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib112","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1046\/j.1523-1755.2001.00997.x","article-title":"Prediction of hypertension in chronic hemodialysis patients","volume":"60","author":"Agarwal","year":"2001","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib113","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1111\/j.0894-0959.2004.17325.x","article-title":"Hypertension and survival in hemodialysis patients","volume":"17","author":"Lynn","year":"2004","journal-title":"Semin Dial"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib114","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib115","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor blocker irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib116","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib117","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1159\/000321688","article-title":"Adherence to antihypertensive agents and blood pressure control in chronic kidney disease","volume":"32","author":"Schmitt","year":"2010","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib118","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.2215\/CJN.01930408","article-title":"Accelerated atherosclerotic calcification and Monckeberg's sclerosis: a continuum of advanced vascular pathology in chronic kidney disease","volume":"3","author":"McCullough","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib119","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1053\/j.ackd.2008.07.009","article-title":"Amplification of atherosclerotic calcification and M\u00f6nckeberg's sclerosis: a spectrum of the same disease process","volume":"15","author":"McCullough","year":"2008","journal-title":"Adv Chronic Kidney Dis"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib120","first-page":"205","article-title":"Determinants of coronary vascular calcification in patients with chronic kidney disease and end-stage renal disease: a systematic review","volume":"17","author":"McCullough","year":"2004","journal-title":"J Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib121","doi-asserted-by":"crossref","first-page":"S115","DOI":"10.1681\/ASN.2005060664","article-title":"Effect of lipid modification on progression of coronary calcification","author":"McCullough","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib122","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1001\/archinternmed.2009.382","article-title":"Annual progression of coronary calcification in trials of preventive therapies: a systematic review","volume":"169","author":"McCullough","year":"2009","journal-title":"Arch Intern Med"},{"issue":"4","key":"10.1016\/j.cpcardiol.2012.12.004_bib123","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1093\/ndt\/gfq725","article-title":"The ADVANCE study: a randomized study to evaluate the effects of Cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis","volume":"26","author":"Raggi","year":"2011","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib124","doi-asserted-by":"crossref","first-page":"2482","DOI":"10.1056\/NEJMoa1205624","article-title":"Effect of Cinacalcet on Cardiovascular Disease in Patients Undergoing Dialysis","volume":"367","author":"Chertow","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib125","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1038\/ki.2008.533","article-title":"Spatial distribution of coronary artery thromboses in patients with chronic kidney disease: implications for diagnosis and treatment","volume":"75","author":"Mukherjee","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib126","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.amjcard.2009.07.043","article-title":"Optimal medical therapy with or without percutaneous coronary intervention for patients with stable coronary artery disease and chronic kidney disease","volume":"104","author":"Sedlis","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib127","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/01.CIR.0000143629.55725.D9","article-title":"Survival after coronary revascularization among patients with kidney disease","volume":"110","author":"Hemmelgarn","year":"2004","journal-title":"Circulation"},{"issue":"11 Suppl 1","key":"10.1016\/j.cpcardiol.2012.12.004_bib128","doi-asserted-by":"crossref","first-page":"S164","DOI":"10.1161\/CIRCULATIONAHA.111.083568","article-title":"Risks of death and end-stage renal disease after surgical compared with percutaneous coronary revascularization in elderly patients with chronic kidney disease","volume":"126","author":"Charytan","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib129","doi-asserted-by":"crossref","first-page":"139","DOI":"10.3904\/kjim.2007.22.3.139","article-title":"Percutaneous coronary intervention versus coronary artery bypass grafting in patients with coronary artery disease and diabetic nephropathy: a single center experience","volume":"22","author":"Bae","year":"2007","journal-title":"Korean J Intern Med"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib130","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.ahj.2004.10.010","article-title":"Association of chronic kidney disease with clinical outcomes after coronary revascularization: the arterial revascularization therapies study (ARTS)","volume":"149","author":"Ix","year":"2005","journal-title":"Am Heart J"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib131","unstructured":"Zheng H, Xue S, Lian F, et al. Meta-analysis of clinical studies comparing coronary artery bypass grafting with percutaneous coronary intervention in patients with end-stage renal disease. Eur J Cardiothorac Surg (in press)."},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib132","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1378\/chest.121.4.1190","article-title":"Off-pump coronary revascularization attenuates transient renal damage compared with on-pump coronary revascularization","volume":"121","author":"Loef","year":"2002","journal-title":"Chest"},{"key":"10.1016\/j.cpcardiol.2012.12.004_bib133","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1200388","article-title":"Off-pump or on-pump coronary-artery bypass grafting at 30 days","volume":"366","author":"Lamy","year":"2012","journal-title":"N Engl J Med"}],"container-title":["Current Problems in Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280612002459?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0146280612002459?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,25]],"date-time":"2020-07-25T13:44:52Z","timestamp":1595684692000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0146280612002459"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":131,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2013,5]]}},"alternative-id":["S0146280612002459"],"URL":"https:\/\/doi.org\/10.1016\/j.cpcardiol.2012.12.004","relation":{},"ISSN":["0146-2806"],"issn-type":[{"value":"0146-2806","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}